Daily Respiratory Research Analysis
Analyzed 188 papers and selected 3 impactful papers.
Summary
Analyzed 188 papers and selected 3 impactful articles.
Selected Articles
1. Nasal CD4+ tissue-resident memory T cells provide cross-protective immunity to influenza.
This study shows that antigen-specific CD4+ TRM persist in nasal tissue after influenza infection and mediate heterosubtypic protection. NT CD4+ TRM are transcriptionally distinct from lung TRM, enriched for Th17 functions, and require the CXCR6–CXCL16 axis for residency; similar Th17-skewed TRM are present in human nasal tissue.
Impact: Defines an upper-airway CD4+ TRM program and its residency mechanism, offering concrete targets (CXCR6–CXCL16 and Th17 TRM) for intranasal vaccines against diverse influenza strains.
Clinical Implications: Supports development of intranasal vaccines/boosters that preferentially elicit Th17-skewed CD4+ TRM in the nasal mucosa; therapeutically, modulation of the CXCR6–CXCL16 axis could enhance local antiviral protection.
Key Findings
- Antigen-specific CD4+ TRM persist in mouse nasal tissue after IAV infection and confer protection upon heterosubtypic challenge.
- Single-cell RNA-seq reveals nasal CD4+ TRM are heterogeneous and transcriptionally distinct from lung TRM.
- The CXCR6–CXCL16 axis is required to promote CD4+ TRM residency in nasal tissue.
- Both mice and humans have a high frequency of Th17-skewed nasal CD4+ TRM that aid viral clearance and reduce tissue damage.
Methodological Strengths
- Integration of mouse infection models with heterosubtypic challenge, single-cell RNA-seq, and mechanistic interrogation of CXCR6–CXCL16.
- Human nasal tissue profiling validating Th17-skewed CD4+ TRM phenotype.
Limitations
- Preclinical mouse-focused study; durability and functional correlates in humans were not tested in vaccine trials.
- Magnitude and kinetics of TRM responses were not linked to clinical endpoints in humans.
Future Directions: Evaluate intranasal vaccine formulations that induce Th17 CD4+ TRM in humans; test adjuvants or chemokine modulation (CXCL16) to enhance nasal TRM residency and cross-protection.
CD4 tissue-resident memory T cells (TRM) are crucial adaptive immune components involved in preventing influenza A virus (IAV) infection. Despite their importance, their physiological role in the upper respiratory tract, the first site of contact with IAV, remains unclear. Here, we find that, after IAV infection, antigen-specific CD4 TRM persist in the nasal tissue (NT) compartment after infection and provide protection upon heterosubtypic challenge. Single-cell RNA-sequencing analysis reveals that NT CD4 TRM are heteroge
2. Clinical presentation and hospitalisation risk of RSV in primary care among children younger than 5 years in Italy in four seasons between 2019 and 2023: a multicentre prospective cohort study.
In a multicenter Italian primary-care cohort of 1410 ARI cases, 40.2% were RSV-positive with mean illness of 15.2 days; symptoms persisted in 40.9% at day 14 and 15.4% at day 30. Hospitalization occurred in 4.4% of RSV-positive children, concentrated in early infancy (16.2% <6 months), while fever failed to distinguish RSV from other pathogens.
Impact: Provides robust, age-specific hospitalization risk and symptom duration data from primary care, directly informing RSV prevention (maternal immunization, infant monoclonals) and surveillance definitions.
Clinical Implications: Supports prioritizing early-infancy RSV prevention and considering extension beyond 24 months; suggests removing mandatory fever from case definitions to improve surveillance sensitivity in primary care.
Key Findings
- RSV was confirmed in 40.2% of 1410 ARI presentations; mean illness duration was 15.2 days.
- Symptoms persisted in 40.9% at day 14 and 15.4% at day 30 among RSV-positive children.
- Overall hospitalization rate was 4.4%, with highest observed risk in <6 months (16.2%); estimated 12.5% at birth.
- Fever did not discriminate RSV from other respiratory pathogens in primary care.
Methodological Strengths
- Prospective multicenter primary-care cohort with RT-PCR confirmation and 14- and 30-day follow-up.
- Age-specific hospitalization risk estimation using observed rates and modeling.
Limitations
- One-country study with a skipped 2020–2021 season; generalizability may be limited.
- Industry funding, although analyses and data handling were conducted independently.
Future Directions: Validate age-risk curves across countries and healthcare settings; evaluate real-world impact of maternal vaccination and long-acting monoclonals on primary-care presentations and hospitalization.
BACKGROUND: Respiratory syncytial virus (RSV) significantly contributes to pediatric morbidity globally. Severe cases are more common in infants and children with underlying health conditions, but even mild infections can result in long-term respiratory issues. While the RSV disease is well-documented in hospital settings, its clinical presentation and hospitalization risk in primary care, the initial point of healthcare access, remains unclear. METHODS: We conducted a multi-center prospective cohort study across multiple regions in Italy during four seasons (from 2019 to 2020 to 2023-2024), excluding 2020-2021. Children ≤5 years with acute respiratory infection (ARI), meeting the WHO case definition for community-based surveillance, were enrolled through primary care pediatricians. Nasopharyngeal swabs were collected and tested with RT-PCR. Clinical data were collected at baseline for all participants and at follow-up intervals of 14 and 30 days post-enrollment for RSV-positive children. FINDINGS: Among 1410 enrolled children with ARIs, RSV was laboratory-confirmed in 40.2% (n = 566). The mean duration of illness among RSV-positive children was 15.2 days (SD 8.8 days), with symptoms persisting in 40.9% of cases at day 14 and 15.4% at day 30. Hospitalization occurred in 4.4% (25/566) of RSV-positive cases, with a median hospital stay of 5 days (IQR: 4-7 days). Younger age was identified as the primary predictor of hospitalization (observed hospitalization rate of 16.2% in children under 6 months), with an estimated hospitalization risk of 12.5% at birth (95% CI: 3.4-33.1%). Fever did not differentiate RSV infection from other respiratory pathogens (p = 0.084). INTERPRETATION: Our study highlights the significant hospitalization risks associated with RSV infections among children presenting in primary care settings, offering detailed age-specific risk estimates crucial for accurate health technology assessments (HTAs) of preventive strategies. The findings strongly support exploring the expansion of RSV preventive interventions beyond the conventional age threshold of 24 months, considering the persisting risk in older children. Furthermore, we emphasize the importance of adopting a case definition without a mandatory fever criterion to enhance the sensitivity of RSV surveillance and thus improve the validity of disease-related estimates. FUNDING: RSV ComNet is a collaborative study funded by Sanofi and AstraZeneca. Study design and planning were undertaken in collaboration with Sanofi researchers. All data collection, analyses, interpretation, manuscript drafting, and the decision to submit for publication were performed independently by the authors. No datasets were shared with the funding parties.
3. Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 study.
In a multicenter, double-blind phase 2 trial, rilzabrutinib (800 or 1200 mg/day) yielded numerically fewer loss-of-asthma-control events versus placebo but without statistical significance, while significantly improving symptom control by week 2 and sustaining benefit through week 12. Diarrhea was the most common adverse event, and no infection signal was observed.
Impact: First randomized evidence that BTK inhibition can improve symptom control in uncontrolled moderate-to-severe asthma, informing a novel oral mechanism beyond current biologics.
Clinical Implications: BTK inhibition may be considered a promising oral add-on strategy for symptom control in uncontrolled asthma; however, lack of significant reduction in exacerbation-related events necessitates larger, longer phase 3 trials and refined patient selection.
Key Findings
- Loss-of-asthma-control events: 38% (800 mg) vs 50% placebo (OR 0.57, p=0.29); 19% (1200 mg) vs 29% placebo (OR 0.58, p=0.21).
- Asthma control improved by week 2 and sustained to week 12 (LS mean difference -0.59, p=0.018 for 800 mg; -0.54, p=0.0013 for 1200 mg).
- Safety: diarrhea most frequent; no increase in infections at either dose.
Methodological Strengths
- Randomized, double-blind, placebo-controlled design across 48 centers in 13 countries
- Pre-specified outcomes with parallel dose cohorts and background therapy withdrawal to stress-test control
Limitations
- Primary clinical events were not statistically reduced and study duration was 12 weeks
- Moderate sample size limits power; withdrawal of background therapy may affect generalizability
Future Directions: Phase 3 trials with longer follow-up, exacerbation-focused endpoints, and biomarker-driven enrichment (e.g., BTK pathway activity) to identify responders.
BACKGROUND: Uncontrolled symptomatic asthma is a substantial challenge for patients despite optimised treatment. Bruton's tyrosine kinase (BTK) plays a key part in immune cell signalling involved in airway inflammation, and its inhibition might improve asthma control. We aimed to explore the effects of BTK inhibition by oral rilzabrutinib on asthma control as well as safety in participants with moderate-to-severe asthma with uncontrolled symptoms. METHODS: This double-blind, placebo-controlled, phase 2 study, which was done at 48 centres across 13 countries, enrolled people aged 18-70 years with physician-diagnosed moderate-to-severe asthma for at least 12 months with uncontrolled symptoms on inhaled glucocorticoids plus a long-acting β